Real-world Study of UTD1 in Chinese Advanced Breast Cancer
To evaluate the efficacy and safety of UTD1 in patients with advanced breast cancer.
Breast Cancer
PFS, Progression free survival, 6 weeks
Adverse events, Number of participants with treatment-related adverse events as assessed by CTCAE v 5.0, 6 weeks
To evaluate the efficacy and safety of UTD1 in patients with advanced breast cancer.